Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (17756)	3/20/1998 9:25:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

Why is this good news for LGND? Ligand is still testing on rats while Hoffman-LaRouche has positive results from human tests. If anything, this could be viewed as negative news for Ligand as a competitor is further along in testing. Why do you view this as a positive for Ligand? --Tony

To: Mudcat who wrote (17756)	3/20/1998 10:19:00 AM
From: David L. Hachey	Respond to of 32384

Mudcat; "Does anyone know why Lgnd doesn't get their good news like the breast cancer rat results to be covered as a news item and not a company press release?" Sure, the company is run by a very good group of scientists. Scientists by nature are generally conservative and consider self-promotion to be tacky. I agree they should better publicize their finding, if for no other reason than to alert the public to the incredible potential of these drugs to cure and/or prevent breast cancer. ...Dave

To: Mudcat who wrote (17756)	3/20/1998 10:41:00 AM
From: SnowShredder	Respond to of 32384

Mudcat, I think the article was announcing an NDA and accelerated approval. Drugs that work in rats may not work in humans. Obviously there is room for improvement...but they are further along than LGND. I'm sure that when LGND submits their NDA they will get good coverage also. Just my 2 cents, Where'd He Go?